EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Effect of denosumab on the incidence of fractures and mortality in patients undergoing hemodialysis: A retrospective cohort study

Arisa Kobayashi, Tatsuhiro Yaginuma, Kazuhiko Kato, Akio Nakashima, Ichiro Ohkido iD, Takashi Yokoo iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0309657 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Arisa Kobayashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Denosumab, Renal Dialysis, Fractures, Bone. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the TSUBASA PROJECT of the Gender Equality Committee of the Japanese Society for Dialysis Therapy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients undergoing hemodialysis are at an elevated risk of fractures; however, substantial evidence for osteoporosis treatment in this population is lacking. We explored the efficacy of denosumab, an anti-IgG2 antibody that targets the receptor activator of nuclear factor-kappa B ligand, in reducing fracture incidence and all-cause mortality in patients undergoing hemodialysis.

Methods

This retrospective cohort study—conducted from December 2013 to December 2022—evaluated the effects of denosumab on fracture incidence and all-cause mortality. Patients who initiated denosumab treatment during the study period were defined as the denosumab group, while those without a history of denosumab administration were defined as the non-denosumab group. Kaplan–Meier curves and log-rank tests were used to assess survival and fracture/mortality risks, respectively. Cox proportional hazards models were used to analyze both fractures and all-cause mortality.

Results

Among 214 patients undergoing hemodialysis, 52 (24.3%) received denosumab. The median age was 73.0 ± 11.5 years, with 92 (43.0%) females, and the median dialysis duration was 59 months (interquartile range, 6–126). During the study, thirty-seven non-denosumab-treated patients had fractures compared to eight in the denosumab group. No significant differences were observed in the unadjusted model (HR, 0.53; 95% confidence interval (CI), 0.24–1.14). Adjusting for competing mortality and clinical factors, the HR remained at 0.64 (95% CI, 0.27–1.51). Regarding all-cause mortality, we found a statistically significant difference in the unadjusted model (HR, 0.61 [95% CI, 0.38–0.98]). A significant reduction in mortality was observed in the adjusted model (HR, 0.46 [95% CI, 0.26–0.80]). Notably, the denosumab group showed a significant decrease in mortality, particularly in cardiovascular disease-related cases (HR, 0.33 [95% CI, 0.14–0.78]).

Conclusions

Denosumab may reduce all-cause mortality in patients undergoing hemodialysis, particularly in those with cardiovascular complications. This finding offers a promising direction for osteoporosis treatment in patients undergoing hemodialysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabRenal DialysisFractures, BoneHumansFemaleMaleRetrospective StudiesAgedIncidenceAged, 80 and overMiddle AgedBone Density Conservation AgentsKaplan-Meier EstimateOsteoporosisProportional Hazards ModelsKidney Failure, Chronic

Substanzen

DenosumabBone Density Conservation Agents

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
  • Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Division of Nephrology, Keijin Hospital, Tokyo, Japan.

ORCID-Profile: Ichiro Ohkido, Takashi Yokoo

Förderung

  • the TSUBASA PROJECT of the Gender Equality Committee of the Japanese Society for Dialysis Therapy

Zitieren

APA

Kobayashi, A., Yaginuma, T., Kato, K., Nakashima, A., Ohkido, I., & Yokoo, T. (2024). Effect of denosumab on the incidence of fractures and mortality in patients undergoing hemodialysis: A retrospective cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0309657

Vancouver

Kobayashi A, Yaginuma T, Kato K, Nakashima A, Ohkido I, Yokoo T. Effect of denosumab on the incidence of fractures and mortality in patients undergoing hemodialysis: A retrospective cohort study. PLOS ONE. 2024. doi:10.1371/journal.pone.0309657

BibTeX
@article{Kobayashi2024,
  author = {Kobayashi, Arisa and Yaginuma, Tatsuhiro and Kato, Kazuhiko and Nakashima, Akio and Ohkido, Ichiro and Yokoo, Takashi},
  title = {Effect of denosumab on the incidence of fractures and mortality in patients undergoing hemodialysis: A retrospective cohort study},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0309657}
}
Kostenlos starten →